Bank of Montreal
CHRS icon

Bank of Montreal’s Coherus Oncology CHRS Stock Holding History

Bank of Montreal’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,690
Closed -$34.1K – 3522
2024
Q4 		$34.1K Buy
+24,690
New +$27.7K ﹤0.01% 3180
2023
Q2 		– Sell
-12,243
Closed -$86.6K – 4002
2023
Q1 		$86.6K Buy
+12,243
New +$95K ﹤0.01% 3272
2022
Q3 		– Sell
-10,949
Closed -$83 – 4105
2022
Q2 		$83 Sell
10,949
-11,350
-51% -$98.7K ﹤0.01% 3500
2022
Q1 		$290K Sell
22,299
-3,410
-13% -$43.4K ﹤0.01% 3211
2021
Q4 		$432K Sell
25,709
-821,614
-97% -$14.4M ﹤0.01% 2500
2021
Q3 		$14.2M Sell
847,323
-5,123
-0.6% -$75.1K 0.01% 1111
2021
Q2 		$12.2M Buy
852,446
+300,252
+54% +$4.25M 0.01% 1164
2021
Q1 		$7.79M Buy
552,194
+146,989
+36% +$2.5M 0.01% 1137
2020
Q4 		$7.12M Buy
405,205
+13,254
+3% +$236K ﹤0.01% 1203
2020
Q3 		$6.86M Buy
391,951
+8,559
+2% +$159K 0.01% 1034
2020
Q2 		$6.85M Buy
383,392
+256,936
+203% +$4.35M 0.01% 1036
2020
Q1 		$1.89M Sell
126,456
-8,785
-6% -$162K ﹤0.01% 1440
2019
Q4 		$2.44M Buy
135,241
+129,810
+2,390% +$2.39M ﹤0.01% 1765
2019
Q3 		$110K Buy
5,431
+275
+5% +$5.5K ﹤0.01% 3241
2019
Q2 		$114K Buy
+5,156
New +$89.5K ﹤0.01% 3258
2019
Q1 		– Sell
-737
Closed -$7K – 4362
2018
Q4 		$7K Buy
737
+378
+105% +$4.37K ﹤0.01% 3979
2018
Q3 		$6K Buy
359
+26
+8% +$461 ﹤0.01% 4057
2018
Q2 		$5K Sell
333
-12,991
-98% -$186K ﹤0.01% 4119
2018
Q1 		$148K Sell
13,324
-1,998
-13% -$21.9K ﹤0.01% 2782
2017
Q4 		$135K Buy
+15,322
New +$164K ﹤0.01% 2868
2017
Q3 		– Sell
-93,550
Closed -$1.34M – 4166
2017
Q2 		$1.34M Buy
+93,550
New +$1.8M ﹤0.01% 1850
2016
Q4 		– Sell
-253
Closed -$7K – 4054
2016
Q3 		$7K Buy
+253
New +$6.9K ﹤0.01% 3629

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Bank of Montreal's CHRS Position: Q1 2025 in Review

Bank of Montreal sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 24,690 shares — an estimated $34.1K sold.

Bank of Montreal first reported a position in CHRS in Q3 2016 and held it in 22 quarters. The position peaked at $14.2M in Q3 2021. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

  • Bank of Montreal reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
  • Bank of Montreal sold 24,690 Coherus Oncology shares in Q1 2025, an estimated $34.1K.
  • Bank of Montreal first reported a position in Coherus Oncology in Q3 2016 and held it in 22 quarters.
  • Bank of Montreal's Coherus Oncology position peaked at $14.2M in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Bank of Montreal's 13F filing for Q1 2025, filed 13 May 2025.